Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE-2 in vitro
K. Khanna, W. Raymond, J. Jin, A. R. Charbit, I. Gitlin, M. Tang, A. D. Werts, E. G. Barrett, J. M. Cox, S. M. Birch, R. Martinelli, H. S. Sperber, S. Franz, S. Pillai, A. M. Healy, , J. V. Fahy
Thiol drugs inhibit SARS-CoV-2 infection in vitro and reduce lung injury in vivo, supporting their potential as COVID-19 treatments.
bioRxiv · Dec 8, 2020 · PreprintMicrobiology